CHIEF INVESTIGATOR
A/Prof Niall Corcoran, Clinician Researcher, Department of Surgery, The University of Melbourne
COLLABORATING INSTITUTIONS | TYPE/ROLE |
| University of Melbourne | LEAD INSTITUTE |
| Walter and Eliza Hall Institute of Medical Research | COLLABORATOR |
| Cambridge University Hospital | COLLABORATOR |
| Cancer Sciences, University of Manchester | COLLABORATOR |
| Dana-Farber Cancer Institute | COLLABORATOR |
| Department of Medical Oncology, Monash Health | COLLABORATOR |
| Ontario Institute for Cancer Research | COLLABORATOR |
| School of Medicine, Faculty of Health at Deakin University | COLLABORATOR |
| School of Medicine, University of Sydney | COLLABORATOR |
| South Australian Health & Medical Research Insitute | COLLABORATOR |
| The Institute of Cancer Research | COLLABORATOR |
| South Australian Health & Medical Research Insitute | COLLABORATOR |
| Peter MacCallum Cancer Centre | COLLABORATOR |
| South West Warrnambool Hospital | COLLABORATOR |
| La Trobe University | COLLABORATOR |
GRANT
3 year (2019-2022) $4m grant from the Prostate Cancer Research Alliance, an Australian Government and Movember Foundation Collaboration
This research program aims to:
- Develop a tissue and blood test that will predict the future risk of progression in men with prostate cancer at the time of diagnosis.
- Develop new ‘curative’ treatments in patients with high risk disease, starting with two clinical studies using novel agents to investigate if treatment effects can be improved.
- Develop new tests for DNA markers that predict how tumours will respond to treatment and using those results to help individualise patient treatment according to their specific tumour type to maximise treatment effect.
Danny Park, Bernie Pope and Chol Hee Jung are all working on the genomic aspects of this project.
For more information, see PRECEPT.